Nyrada Inc. (ASX:NYR)

Market Cap	198.41M +959.9%
Revenue (ttm)	2.40M -26.1%
Net Income	-4.85M
EPS	-0.02
Shares Out	244.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	360,178
Average Volume	827,474
Open	0.8250
Previous Close	0.8150
Day's Range	0.7900 - 0.8400
52-Week Range	0.0770 - 1.4350
Beta	0.92
RSI	42.78
Earnings Date	Feb 17, 2026

About Nyrada

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NYR

Financial Performance

In fiscal year 2025, Nyrada's revenue was 2.40 million, a decrease of -26.07% compared to the previous year's 3.24 million. Losses were -4.85 million, 248.3% more than in 2024.